ClinicalTrials.gg
RecruitingNCT07649655Updated Oct 16, 2026

EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer

A Phase 1 interventional study of EMB-01 and Irinotecan in Unresectable/Metastatic Colorectal Cancer, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
333rd of 894
120 · median 80
Started
2026
with 117 others
Phase 1
130 of 1,139
71 open now
Primary completion
2028-03
later than 480 of 605 live
Registered
1,081st of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 333rd largest by planned enrollment of the 894 interventional ones that give a count, is one of 118 that started in 2026, is one of 130 in phase 1, reaches primary completion later than 480 of the 605 other live ones, and was the 1,081st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

523 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer (CRC), and to determine the recommended Phase II combination dose (RP2CD). The study consists of a dose escalation phase followed by a dose expansion phase. Approximately 30 patients are planned to be enrolled in each combination treatment group across both phases, with a maximum total enrollment of approximately 120 patients.

03

Conditions studied

  • Unresectable/Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female patients aged ≥ 18 and \< 75 years. 2. or cytologically confirmed unresectable or left-sided colorectal cancer (primary tumor located from the splenic flexure to the rectum), with per v1.1.

    3. performance status ≤ 1. 4. Agrees to provide (formalin-fixed paraffin-embedded, collected within 18 months) or newly obtained biopsy tissue. If no eligible archival tissue is available and the patient's clinical condition is not suitable for biopsy, the patient may be screened after confirmation and agreement between the investigator and sponsor.

    5. Adequate organ function within 14 days prior to the first dose of study treatment 6. Prior anti-tumor therapy:

    1. Patients who received any approved or anti-cancer therapy must have discontinued such therapy at least 4 weeks prior to the first dose of study treatment or 5 half-lives of the agent, whichever is shorter.
    2. Patients who received local radiotherapy, bone metastasis radiotherapy, or oral fluoropyrimidines must have discontinued such therapy at least 2 weeks prior to the first dose of study treatment. No therapeutic radiopharmaceuticals within 8 weeks prior to the first dose of EMB-01.

      Prior anti-tumor therapy requirements by combination regimen*:

  • Arm A (irinotecan) and Arm B (TAS-102): Prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, plus prior anti-VEGF therapy (with or without anti-EGFR therapy), with disease progression or intolerance; no prior TAS-102/fruquintinib/regorafenib. If prior anti-EGFR therapy was received, the patient must have achieved CR, PR, or SD, with the last anti-EGFR dose administered at least 4 months prior to the first study drug dose.
  • Arm C (mFOLFOX6): No prior oxaliplatin-based chemotherapy and no prior anti-EGFR therapy.
  • Arm D (FOLFIRI): No prior irinotecan-based chemotherapy and no prior anti-EGFR therapy.

    7. Female patients of or male patients with partners of childbearing potential must use one or more methods from the screening period, continue such methods during study treatment, and until 3 months after the last dose of EMB-01 (for Arm B: 6 months after last TAS-102 dose for both sexes; for Arm C: 9 months after last oxaliplatin dose for females, 6 months for males; for Arm A/D: 6 months after last chemotherapy dose for females, 3 months for males).

    8. Able to swallow and retain oral medications, and has adequate venous access.

Exclusion criteria

Exclusion Criteria:

  • 1. Expected survival \< 3 months. 2. Presence of KRAS/NRAS (exons 2, 3, 4), BRAF V600, positivity (IHC3+ and/or amplification), RET/NTRK fusion, or other molecular alterations that may affect anti-EGFR or cMET therapy efficacy, as detected by central laboratory testing at screening or documented in prior treatment history. (Discussion between investigator and sponsor in writing is recommended if applicable.) 3. Persistent adverse events (AEs) from prior anti-tumor therapy > Grade 2 per v5.0, except alopecia, Grade 2 fatigue, or Grade 2 peripheral neuropathy.

    4. Primary central nervous system (CNS) or symptomatic CNS/. Asymptomatic are allowed if no local radiotherapy is required, or if radiotherapy was completed ≥ 4 weeks prior to first study dose.

    5. Prior treatment with anti-EGFR × cMET bispecific antibody or bispecific ADC. 6. Discontinuation of EGFR inhibitors due to skin toxicity. 7. History of life-threatening , or known allergy to recombinant proteins/ in EMB-01 or any study treatment .

    8. Systemic (> 10 mg prednisone equivalent/day) or other required within 14 days prior to first dose, regardless of disease. Inhaled/topical/ocular/nasal/joint steroids are permitted; adrenal replacement steroids are allowed at >10 mg/day if no active autoimmune disease.

    9. Severe/uncontrolled cardiac disease requiring treatment 10. Use or planned use of -prolonging or rhabdomyolysis-inducing drugs during screening through study end (only Arm C); or known /UGT1A1 strong inhibitors/CYP3A4 inducers/anticholinesterase neuromuscular blockers (only Arms A/D).

    10. Rare hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (only Arm B).

    11. Other serious uncontrolled medical, psychiatric, or familial/endemic conditions that may interfere with study assessments, adherence, or safety (investigator's assessment).

    12. Any condition that, in the investigator's opinion, makes study participation not in the patient's best interest or confounds study evaluations.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm A

    EMB-01 + Irinotecan

    Drug: EMB-01 · Drug: Irinotecan

  • Experimental
    Arm B

    EMB-01 + TAS-102

    Drug: EMB-01 · Drug: TAS-102

  • Experimental
    Arm C

    EMB-01 + 5-Flurouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)

    Drug: EMB-01 · Drug: mFOLFOX6

  • Experimental
    Arm D

    EMB-01 + 5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)

    Drug: EMB-01 · Drug: FOLFIRI

Interventions

  • DrugBafisontamabStudies of BafisontamabBafisontamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).

  • Irinotecan will be administered as intravenous infusion.

  • DrugTAS-102

    TAS-102 will be administered orally.

  • DrugmFOLFOX6

    mFOLFOX6 will be administered as intravenous infusion.

  • DrugFOLFIRI

    FOLFIRI will be administered as intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Safety profile of EMB-01 in combination with chemotherapy will be evaluated by the incidence, severity, seriousness, and relationship of AEs, graded per CTCAE v5.0

    Time frame: From enrollment up to 30 days after last dose of study treatment

  2. Incidence of dose-limiting toxicities (DLTs)

    DLTs will be assessed according to protocol-defined criteria during the first treatment cycle of EMB-01 in combination with chemotherapy regimens

    Time frame: Up to Cycle 1 (28 days)

  3. Tolerability of EMB-01 in combination with chemotherapy

    Outcome Measure: Treatment interruption due to intolerability and relative dose intensity (RDI)

    Time frame: From first dose to 30 days after last dose, up to 2 years

  4. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2CD)

    Determination of the MTD and/or RP2CD of EMB-01 in combination with chemotherapy

    Time frame: Through study completion, up to 2 years

Secondary outcomes

  1. Cmax

    Time frame: Predose, 0, 0.25, 1.5, 24, 48, 72hours post-dose

  2. Ctrough

    Time frame: Predose, 0, 0.25, 1.5, 24, 48, 72hours post-dose

  3. Objective response rate (ORR)

    defined as the proportion of participants achieving CR or PR per RECIST v1.1

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years.

  4. Disease control rate (DCR)

    defined as the proportion of participants achieving CR, PR, or SD per RECIST v1.1

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

  5. Best Overall Response (BOR)

    defined as the best response achieved at any time during study treatment, per RECIST v1.1, categorized as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD).

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

  6. Duration of Response (DOR)

    defined as the time from the first documentation of objective response (CR or PR per RECIST v1.1) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

  7. Clinical Benefit Rate (CBR)

    defined as the proportion of participants achieving CR, PR, or durable SD (≥ 6 months) per RECIST v1.1.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

  8. Progression-Free Survival (PFS)

    defined as the time from the first study treatment dose to the first documentation of progressive disease (PD per RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

  9. Incidence anti-drug antibodies (ADAs)

    Incidence and titer of ADAs against EMB-01 when administered in combination with chemotherapy

    Time frame: From C1D1 pre-dose until 30 days after last dose, up to 2 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 18 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 16, 2026
StartActual
Sep 30, 2026was Jul 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Beijing Cancer Hospital · Beijing, China
  • The Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
Oct 16, 2026
Start date
Jul 2026→Sep 30, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Beijing Cancer Hospital · Beijing, China
    • The Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
    Start date Jul 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07649655
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Sep 30, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Ying Wu
Contact
ywu@epimab.com
86-21-61951000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion